Mutagenesis, Vol. 17, No. 6, 539-550,
November 2002
© 2002 UK Environmental Mutagen Society/Oxford University Press
The significance of telomerase activation and cellular immortalization in human cancer
Brunel Institute of Cancer Genetics and Pharmacogenomics, Faculty of Life Sciences, Brunel University, Kingston Lane, Uxbridge, Middlesex UB8 3PH, UK
Email: robert.newbold{at}brunel.ac.uk
Repression of telomerase in the somatic tissues of humans, and probably other long-lived mammals, appears to have evolved as a powerful protective barrier against cancer. Immortalization in vitro of normal human cells that lack telomerase involves the reactivation of telomerase or, rarely, an alternative (ALT) mechanism for maintaining telomeres. Inactivation of the effectors of replicative senescence, i.e. genes encoding one or more elements of the p16/pRB and/or ARF/p53/p21 anti-proliferative pathways, is required for telomerase depression leading to immortalization. Regulation of telomerase in normal human cells is mediated primarily by transcriptional repression of hTERT, the gene encoding the catalytic subunit of telomerase. Rodent cells do not possess stringent controls on telomerase activity in the soma and this explains why they are so readily immortalized and transformed in culture compared with their human counterparts. Because active telomerase has been found to exist in the proliferative compartments of self-renewing tissues, it is not yet clear whether the telomerase present in 90% of human cancers exists as a consequence of selection of pre-existing telomerase-positive cells during carcinogenesis or through induction of hTERT expression in cells in which it is normally tightly repressed. In support of the latter, chromosome transfer techniques have revealed the presence of genes on normal human chromosomes that are able to extinguish hTERT transcription in cancer cells and induce them to undergo senescence. It is clear that telomerase is obligatory for continuous tumour cell proliferation, clonal evolution and malignant progression. Telomerase therefore represents an attractive target at which to aim new anti-cancer drugs. Results with a variety of telomerase inhibitory strategies in human cancer cells have confirmed that its functional inactivation results in progressive telomere shortening, leading to growth arrest and/or cell death through apoptosis. Promising candidate small molecule inhibitors are beginning to emerge that will form the basis for anti-telomerase drug development.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K.-W. Lee, H. J. Kim, Y. S. Lee, H.-J. Park, J.-W. Choi, J. Ha, and K.-T. Lee Acteoside inhibits human promyelocytic HL-60 leukemia cell proliferation via inducing cell cycle arrest at G0/G1 phase and differentiation into monocyte Carcinogenesis, September 1, 2007; 28(9): 1928 - 1936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Brachner, S. Sasgary, C. Pirker, C. Rodgarkia, M. Mikula, W. Mikulits, H. Bergmeister, U. Setinek, M. Wieser, S.-F. Chin, et al. Telomerase- and Alternative Telomere Lengthening-Independent Telomere Stabilization in a Metastasis-Derived Human Non-Small Cell Lung Cancer Cell Line: Effect of Ectopic hTERT. Cancer Res., April 1, 2006; 66(7): 3584 - 3592. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Rogulski, D. E. Cohen, D. L. Corcoran, P. V. Benos, and E. V. Prochownik Deregulation of common genes by c-Myc and its direct target, MT-MC1 PNAS, December 27, 2005; 102(52): 18968 - 18973. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Horikawa, Y. J. Chiang, T. Patterson, L. Feigenbaum, S.-H. Leem, E. Michishita, V. Larionov, R. J. Hodes, and J. C. Barrett Differential cis-regulation of human versus mouse TERT gene expression in vivo: Identification of a human-specific repressive element PNAS, December 20, 2005; 102(51): 18437 - 18442. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Jiang, J. Bao, P. Li, S. V. Nicosia, and W. Bai Induction of Ovarian Cancer Cell Apoptosis by 1,25-Dihydroxyvitamin D3 through the Down-regulation of Telomerase J. Biol. Chem., December 17, 2004; 279(51): 53213 - 53221. [Abstract] [Full Text] [PDF]
|
|